{"analyses":[{"ciLowerLimit":"1.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.74","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","paramType":"Odds Ratio (OR)","paramValue":"4.36","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"5.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"31.10","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"13.37","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"8.4","value":"4.0"},{"groupId":"OG001","lowerLimit":"11.1","upperLimit":"22.8","value":"16.1"},{"groupId":"OG002","lowerLimit":"28.4","upperLimit":"41.0","value":"34.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"215"}],"units":"Participants"}],"description":"PRO is an assessment of the particpant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants with a baseline PRO scalp hair assessment score of ≥ 3 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}